UAE $10b Israel fund will stress ports and railways globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
Israel research: One Pfizer jab reduces Covid infections 75%
A Sheba Medical Center study published in UK medical journal The Lancet justifies delaying second doses due to vaccine shortages.
The UK peer-reviewed medical journal The Lancet has published a study by Israel s largest hospital, the Sheba Medical Center at Tel Hashomer, of 9,109 of its health-care workers, of whom 7,214 were inoculated against Covid-19 with the Pfizer vaccine. The research supports previous studies that found that the vaccine was extremely effective in reducing severe Covid-19 and easing infection from two weeks after the first jab and justifies the policies of countries delaying second doses due to vaccine shortages.
Opinion
A teenager receives a vaccination against the coronavirus disease (COVID-19), in Tel Aviv, Israel, January 24, 2021. Photo: REUTERS/Ronen Zvulun.
HonestReporting has successfully countered (see here, here, and here) various false media narratives about Israel’s ongoing battle against the coronavirus. Perhaps most pervasive has been the accusation that Jerusalem was preventing the Palestinians from obtaining vaccines. However, the Jewish state has now become the first nation in the world to share COVID-19 inoculations with any external population. Moreover, the Palestinian Authority’s prime minister has announced that tens of thousands of additional jabs would soon be arriving in Ramallah.
Israeli Hospital Partners With National Institutes of Health to Study and Combat COVID-19
Last April, the Sheba Medical Center at Tel Hashomer, located near Tel Aviv, announced the signing of an “emergency agreement” with the Maryland-based National Institutes of Health (NIH) to conduct applied scientific and clinical research studies in order to develop coronavirus-related treatments.
The hospital committed to supplying the NIH’s Vaccine Research Center with blood samples, plasma and the COVID-19 virus itself from infected patients in Israel. This was all made possible due to a series of clinical trials the hospital was conducting on possible treatments, including those being developed by major pharmaceutical companies.
Reliance Group has signed a USD 15 million deal with Israeli company Breath of Health (BOH) to distribute the company s swift COVID-19 breath testing system throughout India, a media report here said. According to the agreement, the Indian corporate giant will purchase hundreds of systems from the Israeli company in a deal valued at USD 15 million and will use them to conduct millions of tests a month at a cost of USD 10 million per month, business portal Calcalist reported. Reliance will also lead research of the system in India and will distribute the platform throughout the country and in the Far East, it added.